Welcome to our dedicated page for Wave Life Scienc SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wave Life Sciences Ltd. (Nasdaq: WVE) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed through EDGAR. Wave is a clinical-stage biotechnology company incorporated in Singapore with ordinary shares listed on The Nasdaq Global Market, and it uses SEC filings to report material events, financial results, securities offerings, and corporate actions.
Recent WVE SEC filings include multiple Forms 8-K describing public offerings of ordinary shares and pre-funded warrants under an automatically effective shelf registration statement on Form S-3ASR, along with related underwriting agreements and legal opinions. Other 8-K filings furnish press releases covering quarterly financial results, clinical data updates for programs such as WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, and corporate presentations made available to investors.
Wave also files 8-Ks to report shareholder meeting outcomes and compensation-related matters, such as amendments to its equity incentive plan and voting results from its annual general meeting. Many of these filings specify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and indicate when press releases or slide decks are incorporated by reference.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items like new securities offerings, changes to compensation plans, or important clinical and financial announcements referenced in 8-Ks. Users can review filing titles, dates, and summarized content, then open the full SEC documents for detailed analysis of Wave Life Sciences’ regulatory and disclosure history.
Kyle Moran filed a notice of proposed sale for 3,564 ordinary shares of WVE, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ around 02/09/2026, with an aggregate market value of $47,935.80. These shares were acquired via restricted stock unit vesting on 02/08/2026 as equity compensation.
During the prior three months, Kyle Moran sold 210,000 ordinary shares on 12/08/2025 for gross proceeds of $3,102,000.00 and 86,000 ordinary shares on 12/09/2025 for gross proceeds of $1,730,250.00. Ordinary shares outstanding were 187,693,059 at the time of the planned sale.
Chris Francis has filed a notice of proposed share sales under Rule 144 for Wave Life Sciences (symbol WVE). The filing covers 1,870 ordinary shares to be sold through Morgan Stanley Smith Barney LLC on or about 02/09/2026 on NASDAQ, with an aggregate market value of 25,151.50 and 187,693,059 ordinary shares outstanding.
The 1,870 shares were acquired on 02/08/2026 through restricted stock unit vesting from the issuer as equity compensation. In the past three months, Francis has already sold 441,031 ordinary shares on 12/08/2025 for gross proceeds of 6,427,084.96 and 9,375 ordinary shares on 01/02/2026 for 150,260.10.
A shareholder has filed a Rule 144 notice to sell 10,411 ordinary shares. The shares are planned to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC at an aggregate market value of $140,027.95, with 187,693,059 shares outstanding.
The securities to be sold were acquired on 02/08/2026 through the vesting of restricted stock units as equity compensation from the issuer, with payment also dated 02/08/2026. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
FMR LLC and Abigail P. Johnson report beneficial ownership of 15,020,982.62 shares of Wave Life Sciences Ltd. common stock, representing 8.5% of the class as of December 31, 2025. FMR LLC holds sole voting power over 15,016,629.00 shares and sole dispositive power over 15,020,982.62 shares.
Abigail P. Johnson is reported with sole dispositive power over 15,020,982.62 shares but no voting power. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Wave Life Sciences.
Wave Life Sciences Ltd. filed a current report noting it has issued a press release titled “Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.” The company highlights regulatory plans around its WVE-006 program for this genetic condition.
The press release is furnished as Exhibit 99.1 and incorporated by reference, while a cover page interactive data file is included as Exhibit 104. The report is signed by President and Chief Executive Officer Paul B. Bolno, M.D.
Wave Life Sciences Ltd. reported a preliminary, unaudited estimate of its cash and cash equivalents, stating that this balance was approximately $602 million as of December 31, 2025. This estimate was included in a press release and an updated corporate presentation made available to the investment community.
The company emphasized that this cash figure is subject to change once full audited financial statements for the year are completed, and any adjustments could be material. Wave Life Sciences also furnished its updated corporate presentation and the related press release as exhibits to this report, while specifying that these materials are being furnished rather than filed for securities law purposes.
Wave Life Sciences Ltd. executive Chris Francis reported an option exercise and share sales in a Form 4. On January 2, 2026, Francis exercised 9,375 share options at an exercise price of $3.14 per share, receiving the same number of ordinary shares. On the same day, he sold 8,080 ordinary shares at a weighted-average price of $15.92 per share and 1,295 ordinary shares at a weighted-average price of $16.70 per share, in multiple transactions within disclosed price ranges. After these transactions, Francis directly owned 25,000 ordinary shares. The filing notes that these fully vested options and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 5, 2025.
GSK plc, through its wholly owned subsidiary Glaxo Group Limited, reported buying 1,470,000 ordinary shares of Wave Life Sciences Ltd. on 12/11/2025 at a price of $19 per share.
After this transaction, the reporting person beneficially owned 18,245,691 Wave Life Sciences ordinary shares, held indirectly via Glaxo Group Limited. The report reflects GSK plc’s role as a shareholder in Wave Life Sciences rather than a change in GSK plc’s own financial results.
Wave Life Sciences Ltd. is conducting a primary offering of 15,789,475 ordinary shares and pre-funded warrants to purchase 2,631,578 ordinary shares. The securities are priced at $19.00 per share and $18.9999 per pre-funded warrant, for a total public offering price of $349,999,744, with estimated net proceeds of approximately $328.4 million after underwriting discounts and expenses. The underwriters have a 30‑day option to buy up to an additional 2,763,157 ordinary shares, which would lift net proceeds to approximately $377.8 million.
The company plans to use the cash primarily to accelerate Phase 2 trials of WVE‑007, its INHBE GalNAc‑siRNA candidate for obesity, and for general corporate purposes. Recent interim Phase 1 data for WVE‑007 showed a single 240 mg dose produced a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat and a 3.2% increase in lean mass at three months, along with durable serum Activin E reductions greater than 75%. As of September 30, 2025, 160,288,481 ordinary shares were outstanding, rising to 176,077,956 on an as‑adjusted basis giving effect to this offering, and new investors face immediate net tangible book value dilution of $16.39 per share.
Wave Life Sciences is raising capital through an underwritten public offering of 15,789,475 ordinary shares at $19.00 per share, plus pre-funded warrants to purchase up to 2,631,578 shares at $18.9999 each, and 2,763,157 additional shares purchased by the underwriters.
The transaction is expected to generate approximately $402.5 million in gross proceeds before fees, with all securities sold by the company. Including these proceeds, Wave Life Sciences expects its cash and cash equivalents to fund operations into the third quarter of 2028 and anticipates having approximately 187,693,059 ordinary shares outstanding after closing.